Drugs Containing Excipient (Inactive Ingredient) DEXTRAN 40

Branded drugs containing DEXTRAN 40 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	ETOPOPHOS	etoposide phosphate	0015-3404	DEXTRAN 40
H2-Pharma LLC	ETOPOPHOS	etoposide phosphate	61269-410	DEXTRAN 40
Acacia Pharma, Ltd.	BYFAVO	remimazolam besylate	71390-011	DEXTRAN 40	2027-07-10

Generic drugs containing DEXTRAN 40 excipient

Company	Ingredient	NDC	Excipient
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	gemtuzumab ozogamicin	0008-4510	DEXTRAN 40
ER Squibb & Sons LLC	etoposide phosphate	0015-3404	DEXTRAN 40
Novartis Pharmaceuticals Corporation	tisagenlecleucel	0078-0846	DEXTRAN 40
Bavarian Nordic A/S	vaccinia virus modified strain ankara-bavarian nordic non-replicating antigen	50632-024	DEXTRAN 40

Market Dynamics and Financial Trajectory for DEXTAN 40

Last updated: February 9, 2026

Overview

Dextran 40 is a high-molecular-weight polysaccharide derived from Leuconostoc mesenteroides bacteria. It is primarily used as a plasma volume expander, drug delivery excipient, and in diagnostic applications. The global market for dextran, including Dextran 40, continues to evolve based on regulatory, technological, and competitive factors.

---

Market Size and Growth Trends

• Global Market Value: Estimated at $250 million in 2022, with a projected Compound Annual Growth Rate (CAGR) of approximately 6% from 2023 to 2030.
• Key Drivers:
  • Growing need for plasma expanders in emergency and surgical settings.
  • Rising adoption in drug delivery systems, especially in biopharmaceutical formulations.
  • Expanding applications in diagnostics and medical imaging.
• Regional Insights:
  • North America dominates with 45% of the market share, driven by high healthcare expenditure and regulatory approvals.
  • Europe accounts for 30%, with significant growth in Germany, France, and the UK.
  • Asia-Pacific shows rapid growth at a CAGR of 8%, due to increased healthcare infrastructure and demand in China and India.

---

Supply Chain and Production Trends

• Manufacturers: Major players include Fuso Pharmaceutical Industries, Chemische Fabrik Budenheim (Budenheim GmbH), and Merck KGaA.
• Production Factors:
  • Fermentation processes using bacterial strains.
  • Raw material availability impacts supply stability.
  • Regulatory standards influence production consistency and scalability.
• Pricing Dynamics:
  • Prices vary between $10 to $25 per gram, depending on purity, volume, and regional market conditions.
  • Supply chain disruptions can temporarily inflate prices, particularly amid raw material shortages or logistic issues.

---

Regulatory Landscape

• Regulatory Approvals:
  • Approved by the FDA (U.S.), EMA (Europe), and other national agencies for plasma volume expansion and compatibility with injectable formulations.
  • Compliance with pharmacopeial standards such as USP, Ph. Eur., and JP influences market access.
• Potential Regulatory Challenges:
  • Stringent approval processes for novel applications.
  • Market entry barriers due to quality and safety standards.

---

Competitive Dynamics

• Market Players:
  • Innovation centers on improving purity, stability, and manufacturing efficiency.
  • Entry of generic manufacturers is increasing price competition.
• Product Differentiation:
  • Focus on molecular weight control and batch consistency.
  • Development of novel formulations with enhanced stability and bioavailability.

---

Financial Trajectory Forecast

Year	Estimated Market Value (USD Millions)	CAGR	Notes
2022	250	—	Base year, established market size
2023	265	6%	Market expansion driven by healthcare demand
2025	297	6%	Increased adoption in diagnostics
2030	380	6%	Stable growth, market maturation

• Revenue Streams:
  • Direct sales to pharmaceutical and biotech companies.
  • Licensing partnerships for proprietary formulations.
• Investment Trends:
  • R&D for improved production and new applications is increasing.
  • Strategic collaborations focus on expanding global footprint and market access.

---

Risks and Challenges

• Regulatory hurdles in new markets.
• Raw material supply chain disruptions.
• Price competition from generics and biosimilars.
• Technological shifts toward alternative excipients.

---

Key Takeaways

• The Dextan 40 market is set for steady growth driven by expanding medical applications.
• North America and Europe dominate the market, with Asia-Pacific emerging as a significant growth zone.
• Price pressures from generics and raw material availability influence profit margins.
• Regulatory compliance remains a critical barrier but also an entry point for established players.
• Ongoing innovation emphasizes product purity, stability, and new delivery methods.

---

FAQs

1. How does regulatory approval impact the Dextan 40 market?
   Regulatory approval determines market access and influences timelines for commercialization. Stringent standards can delay entry but assure product safety, which sustains demand.

2. What are the primary applications of Dextran 40 in healthcare?
   It is primarily used as a plasma volume expander in trauma and surgical procedures, and as an excipient in drug delivery systems and diagnostic agents.

3. How does raw material availability affect Dextran 40 production?
   Dextrin fermentation relies on bacterial strains and raw materials prone to supply fluctuations; shortages can lead to production delays and price increases.

4. Which regions will drive future growth for Dextran 40?
   Asia-Pacific will lead with demographic and infrastructural expansion, followed by continued growth in North America and Europe due to increasing healthcare needs.

5. What innovations could influence the Dextran 40 market?
   Developments in biotechnology to enhance purity, stability, and bioavailability, along with new formulations for targeted drug delivery, will shape future growth.

---

Citations

[1] MarketResearch.com. "Global Dextran Market Report," 2023.
[2] Grand View Research. "Pharmaceutical Excipients Market Size, Share & Trends," 2022.
[3] U.S. Food and Drug Administration (FDA). "Product Approval Database," 2022.
[4] European Medicines Agency (EMA). "Market Authorization Data," 2022.